Health and Healthcare
Targacept Gets Mixed Results on Drug Trials (TRGT, AZN)
Published:
Development stage drug maker Targacept Inc. (NASDAQ: TRGT) is having its troubles these days. Earlier this month the company said it would not seek US Food and Drug Administration approval for its TC-5214 anti-depressant drug following a failed trial. AstraZeneca plc (NYSE: AZN) was Targacept’s partner on the development of TC-5214.
This morning the company announced that another development-stage drug, TC-6987, had failed an exploratory Phase 2 trial and that the company would no longer pursue approval for the drug as a treatment for diabetes. However the drug did meet its trial’s goals as an asthma drug, and Targacept’s CEO noted:
With the positive outcome in our TC-6987 asthma study, we have accomplished our goal of detecting in patients a signal of the potential of NNR [neuronal nicotinic receptors] Therapeutics in the treatment of disorders outside of the CNS, while at the same time further establishing a favorable safety and tolerability profile for this alpha7-selective NNR Therapeutic.
Targacept’s shares are down about -2.4% in early trading today, at $5.26 in a 52-week range of $4.90-$27.22.
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.